Quick DNA test could help stroke patients avoid second clots

NCT ID NCT06292117

Recruiting now Knowledge-focused Sponsor: University of Virginia Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a fast genetic test done in the hospital to see if it helps doctors pick the best blood thinner for stroke patients. Some people have a gene variation that makes the common drug clopidogrel less effective. The test checks for 11 known gene variants and alerts the doctor, so they can prescribe a different medication if needed. The goal is to learn the best way to use this test in routine care and whether it changes prescribing decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CYP2C19 genetic test
What this could lead to: If successful, this could show that a quick genetic test helps doctors pick the right blood thinner for stroke patients, potentially reducing repeat strokes.
What could go wrong: This is an observational study focused on implementation, not on proving the test directly improves outcomes. The test only looks at 11 gene variants, and results may not change prescribing in all cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYP2C19 POLYMORPHISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke transient ischemic attack

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYP2C19 POLYMORPHISM ISCHEMIC STROKE

Contacts and locations

Locations

University of Virginia
RECRUITING

Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.